Ranitidine Recalls Begin As European Regulators Take Action
Executive Summary
OTC ranitidine products are among the first to be recalled in Europe following the discovery of a human carcinogen in ranitidine-based drugs.With investigations underway worldwide, regulators across Europe are split into two camps: immediate action or wait and see.
You may also be interested in...
Nitrosamine Issue Presages Paradigm Shift In Quality
The detection of cancer-causing impurities in drugs with well-established safety profiles may force regulators across the globe to revise their approach for evaluating quality.
Nitrosamine Episode Could Lead To Paradigm Shift In Quality
The detection of cancer-causing impurities in drugs with well-established safety profiles may force regulators across the globe to revise their approach for evaluating quality.
US FDA Questions Valisure’s Zantac Carcinogenicity Findings
As ranitidine suspensions and recalls mount worldwide, US agency says heat of pharmacy lab's test made nitrosamine levels appear high.